Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype.

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder characterized by complement-mediated hemolysis due to deficiencies of glycosylphosphatidylinositol-anchored proteins (GPI-APs) in subpopulations of blood cells. Acquired mutations in the X-linked phosphatidylinositol glycan-class A (PIG-A) gene appear to be the characteristic and pathogenetic cause of PNH. To develop a gene therapy approach for PNH, a retroviral vector construct, termed MPIN, was made containing the PIG-A complementary DNA along with an internal ribosome entry site and the nerve growth factor receptor (NGFR) as a selectable marker. MPIN transduction led to efficient and stable PIG-A and NGFR gene expression in a PIG-A-deficient B-cell line (JY5), a PIG-A-deficient K562 cell line, an Epstein-Barr virus-transformed B-cell line (TK-14(-)) established from a patient with PNH, as well as peripheral blood (PB) mononuclear cells from a patient with PNH. PIG-A expression in these cell lines stably restored GPI-AP expression. MPIN was transduced into bone marrow mononuclear cells from a patient with PNH, and myeloid/erythroid colonies and erythroid cells were derived. These transduced erythroid cells restored surface expression of GPI-APs and resistance to hemolysis. These results indicate that MPIN is capable of efficient and stable functional restoration of GPI-APs in a variety of PIG-A-deficient hematopoietic cell types. Furthermore, MPIN also transduced into PB CD34(+) cells from a normal donor, indicating that MPIN can transduce primitive human progenitors. These findings set the stage for determining whether MPIN can restore PIG-A function in multipotential stem cells, thereby providing a potential new therapeutic option in PNH.

[1]  K. Kangawa,et al.  Initial enzyme for glycosylphosphatidylinositol biosynthesis requires PIG‐P and is regulated by DPM2 , 2000, The EMBO journal.

[2]  T. Standiford,et al.  Urokinase Receptor-Deficient Mice Have Impaired Neutrophil Recruitment in Response to Pulmonary Pseudomonas aeruginosa Infection1 , 2000, The Journal of Immunology.

[3]  B. Sullenger,et al.  An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies , 2000, Gene Therapy.

[4]  Y. Murakami,et al.  Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. , 1999, Blood.

[5]  T. Kinoshita,et al.  Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease , 1999, American journal of hematology.

[6]  P. Romagnoli,et al.  Defective TCR signaling events in glycosylphosphatidylinositol-deficient T cells derived from paroxysmal nocturnal hemoglobinuria patients. , 1999, International immunology.

[7]  H. Esperou,et al.  Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[8]  H. Mizoguchi,et al.  CD59‐deficient blood cells and PIG‐A gene abnormalities in Japanese patients with aplastic anaemia , 1999, British journal of haematology.

[9]  L. Luzzatto,et al.  Bone marrow transplants for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[10]  B. Brewer,et al.  Correction of the PNH defect by GPI-anchored protein transfer. , 1998, Blood.

[11]  E. Gilboa,et al.  Multiparameter-fluorescence activated cell sorting analysis of retroviral vector gene transfer into primitive umbilical cord blood cells. , 1998, Experimental hematology.

[12]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[13]  W. Rosse,et al.  The natural history of paroxysmal nocturnal hemoglobinuria. , 1997, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[14]  N. E. Hansen,et al.  Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria , 1996, British journal of haematology.

[15]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[16]  E. Gilboa,et al.  High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes. , 1996, Gene therapy.

[17]  J. Yu,et al.  A knock-out model of paroxysmal nocturnal hemoglobinuria: Pig-a(-) hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Wittwer,et al.  Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. , 1996, Blood.

[19]  H. Sakamaki,et al.  Plasma soluble interleukin‐2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome , 1996, British journal of haematology.

[20]  T. Kinoshita,et al.  Analysis of PIG‐A gene in a patient who developed reciprocal translocation of chromosome 12 and paroxysmal nocturnal hemoglobinuria during follow‐up of aplastic anemia , 1996, American journal of hematology.

[21]  C. Miller,et al.  Resolution of Budd‐Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria , 1996, British journal of haematology.

[22]  J. Platt,et al.  In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. , 1995, Science.

[23]  F. Sigaux,et al.  Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. , 1995, Blood.

[24]  T. Miyata,et al.  Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1994, The New England journal of medicine.

[25]  L. Luzzatto,et al.  Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[27]  T. Miyata,et al.  The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. , 1993, Science.

[28]  T. Kinoshita,et al.  Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria , 1993, The Journal of experimental medicine.

[29]  J. Takeda,et al.  Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria. , 1992, International immunology.

[30]  S. Jang,et al.  Construction of a bifunctional mRNA in the mouse by using the internal ribosomal entry site of the encephalomyocarditis virus , 1992, Molecular and cellular biology.

[31]  R. Schmidt,et al.  Differences in activation of normal and glycosylphosphatidylinositol-negative lymphocytes derived from patients with paroxysmal nocturnal hemoglobinuria. , 1992, Journal of immunology.

[32]  R. Storb,et al.  Marrow transplantation for paroxysmal nocturnal hemoglobinuria , 1992, American journal of hematology.

[33]  R. Mohney,et al.  Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones. , 1992, The Journal of biological chemistry.

[34]  R. Ware,et al.  Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. , 1991, The New England journal of medicine.

[35]  W. Rosse.  Dr Ham's test revisited [editorial] , 1991 .

[36]  K. Zsebo,et al.  Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. , 1991, Experimental hematology.

[37]  W. Garland,et al.  The cytolytic toxin aerolysin must aggregate to disrupt erythrocytes, and aggregation is stimulated by human glycophorin , 1988, Infection and immunity.

[38]  B. Haynes,et al.  Human Erythrocyte Antigens , 1987 .

[39]  G. Sakaguchi,et al.  Purification and characterization of an Aeromonas hydrophila hemolysin , 1986, Journal of clinical microbiology.

[40]  R. Schreiber,et al.  Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes , 1983, The Journal of experimental medicine.

[41]  Medicixisohe WO Ciienschrift.  Paroxysmale Haemoglobinurie , 1882 .

[42]  村上 良子.  Different Roles of Glycosylphosphatidylinositol in Various Hematopoietic Cells as Revealed by Mouse Model of Paroxysmal Nocturnal Hemoglobinuria , 2001 .

[43]  F. Benvenuto,et al.  Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. , 2000, Haematologica.

[44]  V. Rosti.  The molecular basis of paroxysmal nocturnal hemoglobinuria. , 2000, Haematologica.

[45]  R. Ware,et al.  Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. , 1998, Hematopathology and molecular hematology.

[46]  H. Heimpel,et al.  A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. , 1995, Experimental hematology.

[47]  T. Kinoshita,et al.  Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. , 1995, Advances in immunology.

[48]  R. Schmidt,et al.  Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. , 1994, Blood.

[49]  C. Bordignon,et al.  Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. , 1994, Blood.

[50]  S. Fidel,et al.  Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. , 1994, Blood.

[51]  W. Rosse.  Dr Ham's test revisited. , 1991, Blood.

[52]  L. Luzzatto,et al.  7 Paroxysmal nocturnal haemoglobinuria , 1989 .

[53]  M. Telen,et al.  Human erythrocyte antigens. III. Characterization of a panel of murine monoclonal antibodies that react with human erythrocyte and erythroid precursor membranes. , 1987, Vox sanguinis.